<?xml version="1.0" encoding="UTF-8"?>
<ref id="B110">
 <label>110.</label>
 <mixed-citation publication-type="book">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Rocconi</surname>
    <given-names>RP</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Grosen</surname>
    <given-names>EA</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Ghamande</surname>
    <given-names>SA</given-names>
   </name>
  </person-group>
  <etal/>
  <article-title>Randomized Double-Blind Placebo Controlled Trial of Primary Maintenance Vigil Immunotherapy (VITAL study) in Stage III/IV Ovarian Cancer: Efficacy Assessment in BRCA1/2-wt Patients (Late Breaking Oral Presentation)</article-title>. 
  <source>Presented at: 
   <italic toggle="yes">Society of Gynecologic Oncology Annual Meeting on Women's Cancer</italic>.
  </source>
  <publisher-loc>Toronto, Canada</publisher-loc> (
  <year>2020</year>). 
 </mixed-citation>
 <note>
  <p>•• Recent Vigil clinical trial results in ovarian cancer.</p>
 </note>
</ref>
